Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

Mabel Mardones, MD, Rocky Mountain Cancer Centers, discusses the future of HR+/HER2– breast cancer treatment, focusing on the importance of biomarkers and the potential of SIRDs to improve patient ...

Today announced third quarter financial results and operational highlights. Highlights include BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms ...

A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling ...

Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast ...

Significant Ki-67 protein suppression in HR-positive, HER2-negative breast cancer was seen among patients treated with ...

Researchers found the three-drug therapy delayed disease progression by an average of 15 months compared with 7.3 months in ...

Adam Brufsky, MD, PhD, professor of medicine at the University of Pittsburgh School of Medicine; Megan Kruse, MD, breast medical oncologist at Cleveland Clinic; and Ruta Rao, MD, professor of medicine ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

Adam Brufsky, MD, PhD, professor of medicine at the University of Pittsburgh School of Medicine; Megan Kruse, MD, breast medical oncologist at Cleveland Clinic; and Ruta Rao, MD, professor of medicine ...

A powerful, three-drug therapy for aggressive advanced breast cancer doubles the length of time before the cancer progresses, ...

Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 ...